Skip to main content

AHA Guidelines: ICD Indications in HCM


ICD Indications in Hypertrophic Cardiomyopathy (HCM)


Hypertrophic cardiomyopathy (HCM) is one of the most common inherited cardiac disorders and an important cause of sudden cardiac death (SCD), particularly in young individuals and athletes. Implantable cardioverter-defibrillator (ICD) therapy is the most effective strategy for preventing SCD in these patients. Current recommendations are mainly derived from the American Heart Association and American College of Cardiology guidelines.



---


Purpose of ICD in HCM


The primary role of an ICD in HCM is prevention of sudden cardiac death due to malignant ventricular arrhythmias such as ventricular tachycardia or ventricular fibrillation.


ICD therapy is used in two situations:


• Secondary prevention

• Primary prevention (based on risk stratification)



---


1. Secondary Prevention ICD


ICD implantation is strongly recommended (Class I indication) in HCM patients with any of the following:


• Prior cardiac arrest due to ventricular fibrillation

• Sustained ventricular tachycardia causing hemodynamic instability

• Documented spontaneous sustained VT


These patients have a very high risk of recurrent malignant arrhythmias, and ICD therapy significantly reduces mortality.



---


2. Primary Prevention ICD


Primary prevention focuses on identifying patients at high risk of sudden cardiac death.


According to the American Heart Association / American College of Cardiology 2020 guidelines, ICD implantation is reasonable (Class IIa) when one or more major risk markers are present.


Major Risk Factors for SCD in HCM


1. Massive LV Hypertrophy


Maximum LV wall thickness ≥ 30 mm on echocardiography or cardiac MRI.


2. Family History of SCD


Sudden cardiac death in a first-degree relative due to HCM, especially before age 50.


3. Unexplained Syncope


Recent unexplained syncope suspected to be arrhythmic.


4. LV Apical Aneurysm


Presence of a left ventricular apical aneurysm detected on imaging.


5. LV Systolic Dysfunction


Left ventricular ejection fraction ≤ 50%.


6. Extensive Late Gadolinium Enhancement


Extensive myocardial fibrosis on cardiac MRI (>15% LV mass).



---


Additional Risk Modifiers


These factors may support ICD decision-making but are not standalone indications:


• Non-sustained ventricular tachycardia on Holter monitoring

• Abnormal blood pressure response to exercise

• Severe left atrial enlargement

• LV outflow tract obstruction

• High risk score on the HCM Risk‑SCD Score



---


ESC Risk Calculator Approach


The European Society of Cardiology recommends using the HCM Risk-SCD calculator to estimate 5-year risk of sudden cardiac death.


Risk-Based Recommendations


• ≥ 6% risk → ICD recommended

• 4–6% risk → ICD should be considered

• < 4% risk → ICD usually not recommended


Variables used in the risk model include:


• Age

• Maximum LV wall thickness

• Left atrial diameter

• LVOT gradient

• Family history of SCD

• Non-sustained VT

• Unexplained syncope



---


Special Situations


Pediatric HCM


Risk stratification differs slightly and often includes:


• Extreme hypertrophy

• Unexplained syncope

• NSVT

• Family history of SCD


Athletes


HCM remains a major cause of sudden death in athletes, and ICD may be recommended even with borderline risk profiles.



---


Complications of ICD in HCM


Although life-saving, ICD therapy has potential complications:


• Inappropriate shocks

• Lead failure

• Infection

• Psychological impact

• Device replacement in young patients


Therefore, careful risk-benefit assessment and shared decision-making are essential.



---


Key Takeaway


ICD implantation is the most effective strategy for preventing sudden cardiac death in hypertrophic cardiomyopathy. Secondary prevention indications are clear, while primary prevention requires careful evaluation of major risk markers such as massive hypertrophy, family history of SCD, syncope, LV dysfunction, and apical aneurysm.



Comments

Popular posts from this blog

π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š

 π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š in  Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts.  The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.

Acute Treatment of Hyperkalemia

Acute Treatment of Hyperkalemia – A Practical, Bedside-Oriented Guide Hyperkalemia is a potentially life-threatening electrolyte abnormality that demands prompt recognition and decisive management. The danger lies not only in the absolute potassium value but in its effects on cardiac conduction, which can rapidly progress to fatal arrhythmias. Acute treatment focuses on three parallel goals: stabilizing the cardiac membrane, shifting potassium into cells, and removing excess potassium from the body. Understanding this stepwise approach helps clinicians act quickly and rationally in emergency settings. Why Hyperkalemia Is Dangerous Potassium plays a key role in maintaining the resting membrane potential of cardiac myocytes. Elevated serum potassium reduces the transmembrane gradient, leading to slowed conduction, ECG changes, ventricular arrhythmias, and asystole. Importantly, ECG changes do not always correlate with potassium levels, so treatment decisions should be based on clinical c...

2025 AHA/ACC Hypertension Guidelines Key points

  2025 AHA/ACC Hypertension Guidelines Explained: A Clear Summary for Clinicians and Students Hypertension remains one of the most significant contributors to cardiovascular morbidity and mortality worldwide. With continual refinement of evidence and risk-based strategies, the 2025 AHA/ACC Hypertension Guidelines bring an updated, practical approach that clinicians can use in daily practice. To make learning easier, I’ve created a clean and modern infographic summarizing all major recommendations. You can download it below and use it for study, teaching, or clinical reference. Download Infographic (PNG): 2025 Hypertension Guideline Infographic This post breaks down the key points from the guidelines and complements the infographic for a complete understanding. --- BP Categories: Understanding the Updated Thresholds The guidelines maintain the well-established classification of blood pressure: Normal: <120 / <80 Elevated: 120–129 / <80 Stage 1 Hypertension: 130–139 and/or 8...